Please provide your email address to receive an email when new articles are posted on . In the SENSCIS-ON trial, two-thirds of patients with systemic sclerosis-associated interstitial lung disease who ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the SENSCIS ® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVC a) in ...

During nintedanib (Ofev) treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side effect, ...

Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS™ (Safety and Efficacy ofNintedanib in Systemic SClerosIS) study. The global Phase III trial, which is now ...

The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic ...

Data from a literature review of 41 studies were analyzed and subsequently leveraged to create a survey among physicians on the use of 4 targeted therapies in systemic sclerosis-interstitial lung ...

The designation was supported by the Investigational New Drug application (IND) for the treatment of SSc-ILD and the anticipated safety and efficacy data from the Phase 3 double-blind, randomized, ...

The FDA has granted Orphan Drug designation to nintedanib (Boehringer Ingelheim) for the treatment of systemic sclerosis (SSc, or scleroderma), including the associated interstitial lung disease ...

Please provide your email address to receive an email when new articles are posted on . Early intervention is critical for patients who are likely to progress to serious complications from systemic ...

Suggested remit: To appraise the clinical and cost effectiveness of nintedanib within its marketing authorisation for treating interstitial lung disease caused by systemic sclerosis. Following on from ...